BrainStorm Cell (BCLI) grants director Naor Nir 180K stock options

Rhea-AI Filing Summary

BrainStorm Cell Therapeutics director Naor Nir received a new stock option grant. He was awarded options to buy 180,000 shares of common stock at an exercise price of $0.70 per share under the company’s 2014 Stock Incentive Plan.

According to the vesting terms, 50% of the options vest on the grant date, and the remaining 50% vest on the six‑month anniversary of the grant date, provided he remains employed by the company through each vesting date. Following this award, he holds options covering 180,000 shares from this grant, which expire on February 26, 2036.

Insights

Equity compensation analyst

Routine option grant compensates a director with equity-linked incentives.

Director Naor Nir received stock options for 180,000 shares of BrainStorm Cell Therapeutics common stock at an exercise price of $0.70 per share. The award is classified as a grant or other acquisition, not an open-market purchase.

The options vest 50% on the grant date and 50% after six months, contingent on continued employment, and expire on February 26, 2036. This structure ties part of his compensation to the company’s long-term share performance without immediate cash outlay.

Because there are no sales or exercises reported and no remaining derivative positions beyond this grant in the excerpt, the filing mainly documents a standard equity incentive award rather than a directional trading signal by the director.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Naor Nir

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	180,000	$0.70	$126K

Holdings After Transaction: Stock Option (Right to Buy) — 180,000 shares (Direct, null)

Footnotes (1)

1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

Key Figures

Option grant size: 180,000 options Exercise price: $0.70 per share Expiration date: February 26, 2036 +2 more

5 metrics

Option grant size 180,000 options Director stock option award covering common shares

Exercise price $0.70 per share Exercise price for granted stock options

Expiration date February 26, 2036 Option term end date for this grant

Immediate vesting portion 50% of award Vests on the grant date, subject to service

Six-month vesting portion 50% of award Vests six months after grant if still employed

Key Terms

Stock Option, 2014 Stock Incentive Plan, vest, Grant, award, or other acquisition

4 terms

Stock Option financial

"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2014 Stock Incentive Plan financial

"granted under the Issuer's 2014 Stock Incentive Plan."

vest financial

"The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Naor Nir

(Last) (First) (Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK NEW YORK 10019

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	$0.7	02/26/2026		A		180,000		(2)	02/26/2036	Common Stock	180,000	$0.7(1)	180,000	D

Explanation of Responses:

1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.

2. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

	/s/ Nir Naor	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Naor Nir report in his Form 4 for BrainStorm Cell (BCLI)?

Naor Nir reported receiving a grant of stock options for 180,000 shares of BrainStorm Cell common stock. The options were awarded as equity compensation, not bought on the open market, and are tied to his ongoing service with the company.

How many BrainStorm Cell (BCLI) shares are covered by Naor Nir’s option grant?

The option grant covers 180,000 shares of BrainStorm Cell common stock. These shares are issuable upon exercise of the options, giving Nir the right, but not the obligation, to purchase that number of shares at a fixed price if he chooses.

What is the exercise price and expiration date of Naor Nir’s BCLI options?

The options have an exercise price of $0.70 per share and expire on February 26, 2036. This means Nir can buy BrainStorm Cell shares at $0.70 any time before expiration, subject to vesting and the terms of the plan.

How do Naor Nir’s BrainStorm Cell (BCLI) stock options vest?

The options vest in two equal parts: 50% of the award vests on the grant date and the remaining 50% vests six months later. Vesting is conditioned on Nir remaining employed by BrainStorm Cell through each vesting date.

Are Naor Nir’s BCLI option transactions open-market buys or compensation grants?

They are compensation grants, not open-market purchases. The Form 4 classifies the transaction as a grant or award acquisition under the company’s 2014 Stock Incentive Plan, providing equity-based pay rather than a discretionary stock market trade.